Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03448042 · ClinicalTrials.gov registry record · Phase 1
A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers
A Phase 1 study of Solid Tumors, sponsored by Genentech.
- Active
- Registry status
- Phase 1
- Development phase
- 123
- Enrollment target
- 20
- Study locations
NCT03448042: Active Phase 1 study of Solid Tumors, sponsored by Genentech.
NCT03448042 is a Phase 1 study of Solid Tumors that is active but no longer recruiting, run by Genentech. The registered enrollment target is 123 participants, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (57% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03448042, a Phase 1 study of Solid Tumors, is active but no longer recruiting, sponsored by Genentech.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 123 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the safety, tolerability, and pharmacokinetics of Runimotamab administered intravenously as a single agent and in combination with Trastuzumab in participants with locally advanced or metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-expressing cancers.
Conditions Studied
Interventions
- DRUG Trastuzumab
- DRUG Tocilizumab
- DRUG Runimotamab
Study Locations (20)
Other
- Grand Hopital de Charleroi asbl - Charleroi
- Rigshospitalet-Blegdamsvej 9 - Copenhagen
- Institut Claudius Regaud - Toulouse
- National Cancer Center East - Chiba
- Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis - Amsterdam
- National Cancer Centre - Singapore
- Asan Medical Center - Seoul
- Seoul National University Hospital - Seoul
Connecticut
- Yale University - New Haven
Michigan
- Washington University - Saint Louis
New York
- Memorial Sloan Kettering Cancer Center - New York
Tennessee
- SCRI Oncology Partners - Nashville
Texas
- MD Anderson Cancer Center - Houston
Victoria
- Peter MacCallum Cancer Centre - Melbourne
Ontario
- Princess Margaret Hospital - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 123 participants |
| Start Date | 2018-06-06 |
| Est. Completion | 2026-11-30 |
| Phase | Phase 1 |
What the registry record for NCT03448042 still lists
NCT03448042 is an interventional study that assigns participants to a tested intervention. The registered 123 participants enrollment target is mid-sized for trials with a published cap, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (57% lower).
The record links to 1 condition, with Solid Tumors appearing as the primary indexed condition, and to 3 interventions - of which Trastuzumab is the first listed.
NCT03448042 names 20 study sites across 13 states, led by Other, Connecticut, Michigan.
Frequently Asked Questions
What is clinical trial NCT03448042 about?
NCT03448042 is a clinical study titled "A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers". This study will evaluate the safety, tolerability, and pharmacokinetics of Runimotamab administered intravenously as a single agent and in combination with Trastuzumab in participants with locally advanced or metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-expressing cancers.
What is the current status of trial NCT03448042?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 123 participants. The study started on 2018-06-06. Estimated completion is 2026-11-30.
What conditions does trial NCT03448042 study?
This clinical trial studies the following conditions: Solid Tumors.
What interventions are being tested in trial NCT03448042?
The interventions under investigation include: Trastuzumab (DRUG), Tocilizumab (DRUG), Runimotamab (DRUG).
Who is sponsoring clinical trial NCT03448042?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03448042 being conducted?
This trial has 20 study locations across Connecticut, Michigan, New York, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03448042's enrollment target sits among peer trials
123 47th of 125 higher than 79 of 125 other Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of INCB123667 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
RECRUITING · Phase 1
-
Study of AUBE00 in Patients With Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05285891 · 123 participants · Phase 4
Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis
- NCT05334368 · 123 participants · Phase 3
Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
- NCT06088355 · 123 participants · NA
Moderate Versus High Volume Light-Moderate Intensity Exercise for People With Moderate Parkinson's Disease
- NCT06111131 · 123 participants · NA
Ancora-SB Overtube Complete Positioning and Optical Visualization During Endoscopic Procedures
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI